Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT05151679 Available - Clinical trials for Iron Deficiency Anemia of Pregnancy

Chelated Oral Iron Versus Intravenous Iron Sucrose for Treatment of Iron Deficiency Anemia Late in Pregnancy

Start date: n/a
Phase:
Study type: Expanded Access

compare the efficacy and safety of intravenous iron sucrose versus chelated oral iron in the treatment of iron deficiency anemia late in pregnancy.

NCT ID: NCT05100134 Available - Clinical trials for Non-small Cell Lung Cancer (NSCLC)

Managed Access Programs for LDK378, Ceritinib

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this registration is to list Managed Access Programs (MAPs) related to LDK378, Ceritinib.

NCT ID: NCT04929158 Available - Clinical trials for ST Elevation Myocardial Infarction

Comparison of Clinical Outcomes of IVUS -Guided and Angiography-guided PCI in Patients With Acute STEMI

Start date: n/a
Phase:
Study type: Expanded Access

To compare the long-term clinical outcomes of IVUS-guided vs angiography-guided PCI in patients with acute STEMI

NCT ID: NCT04853602 Available - Clinical trials for Merkel Cell Carcinoma

IFx-Hu2.0 Expanded Access Program

Start date: n/a
Phase:
Study type: Expanded Access

Expanded access requests for IFx-Hu2.0 may be considered for the treatment of adult patients (greater than or equal to 18 years of age) with stage III through IV cutaneous melanoma, advanced Merkel cell carcinoma (MCC), or advanced cutaneous squamous cell carcinoma (cSCC) who have failed all available treatment options. To request access, use Responsible Party contact information provided in this record..

NCT ID: NCT04830202 Available - Clinical trials for Non-Small Cell Lung Cancer (NSCLC)

Expanded Access to Telisotuzumab Vedotin

Start date: n/a
Phase:
Study type: Expanded Access

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Telisotuzumab vedotin prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

NCT ID: NCT04768907 Available - Clinical trials for Steroid Refractory GVHD

Early Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host Disease

ATLAS
Start date: n/a
Phase:
Study type: Expanded Access

MaaT013 is still in clinical development phase and is not approved yet for marketing in any region. During the development program, MaaT Pharma has undertaken initial development with closely related product candidates, leading to the Phase II HERACLES study in which MaaT013 preliminary safety and efficacy were assessed in the context of steroid-resistant, gastrointestinal aGraft versus Host Disease (SR-GI-aGvHD). In addition, a pivotal Phase III study (ARES trial) is planned. In the absence of medical options in patients with gastrointestinal acute GvHD refractory to multiple lines of treatment, this early access program has been implemented.

NCT ID: NCT04745637 Available - Clinical trials for Primary Myelofibrosis (PMF)

Managed Access Programs for INC424, Ruxolitinib

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this registration is to list Managed Access Programs (MAPs) related to INC424, Ruxolitinib

NCT ID: NCT04729062 Available - C3 Glomerulopathy Clinical Trials

C3G/Primary IC-MPGN EAP

Start date: n/a
Phase:
Study type: Expanded Access

This is an Early Access Program (EAP) which will provide access to pegcetacoplan for eligible participants with C3G and Primary IC-MPGN.

NCT ID: NCT04682834 Available - Clinical trials for Acute Pyelonephritis

Expanded Access Use of Sulopenem Etzadroxil/Probenecid for Complicated Urinary Tract Infection

Start date: n/a
Phase:
Study type: Expanded Access

Sulopenem etzadroxil/probenecid is available to clinicians through an Expanded Access Program for the treatment of complicated urinary tract infections due to quinolone nonsusceptible uropathogens after an initial course of effective intravenous therapy. The investigational product may be requested by sending an email to the Sponsor (EAProgram@iterumtx.com), as listed on the Reagan Udall EAP Navigator website (https://navigator.reaganudall.org/company-directory/i).

NCT ID: NCT04681248 Available - Ovarian Cancer Clinical Trials

Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors

Start date: n/a
Phase:
Study type: Expanded Access

An Expanded Access Protocol for use of DKN-01 for the treatment of advanced solid tumors.